The time horizons of formal decision analyses

QJM: An International Journal of Medicine

Volumn 100, Issue 6, 2007, Pages 383-388

  Benbassat, J ^a   Baumal, R ^b  

^a MYERS JDC BROOKDALE INSTITUTE   (Israel)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; CLINICAL DECISION MAKING; DISEASE COURSE; FOLLOW UP; HEALTH HAZARD; HUMAN; LIFE EXPECTANCY; LIFESPAN; NOTE; PRIORITY JOURNAL; PROBABILITY; PUBLICATION; QUALITY ADJUSTED LIFE YEAR;

EID: 34447547874     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm030     Document Type: Note

References (46)

1. Beck JR, Pauker SG. The Markov Process in medical prognosis. Med Dec Making 1983; 3:419-58.
2. Kuntz K, Wein M. Life expectancy biases in clinical decision modeling. Med Decis Making 1995; 15:158-69.
3. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: Follow-up study after two decades. Br Med J 1998; 317:167-71.
4. Benbassat J, Zajicek G, van Oortmarssen GJ, Ben-Dov I, Eckman MH. Inaccuracies in estimates of life expectancy of patients with bronchial cancer in clinical decision making. Medical Dec Making 1993; 13 237-44.
5. Hakama M, Hakulinen T. Estimating the expectation of life in cancer survival studies with incomplete follow-up information. J Chron Dis 1977; 30:585-97.
6. Hankey BF, Myers MH. Black/white differences in bladder cancer patient survival. J Chron Dis 1987; 40:65-73.
7. The atrial fibrillation investigators.Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-57.
8. Holland RR, Ellis CA, Geller BM, Plante DA, Secker-Walker RH. Life expectancy estimation with breast cancer: Bias of the declining exponential function and an alternative to its use. Med Decis Making 1999; 19:385-93.
9. The SEER public access record. Submission: August 1987. Version: June 1988. Surveillance, Epidemiology, End Results. Bethesda MD, The National Cancer Institute Demographic Analysis Section, 1988.
10. Petty GW, Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO, Brown RD. Ischemic stroke subtypes. A population based study of functional outcome, survival and recurrence. Stroke 2000; 31 1062-8.
11. Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP. The high risk of stroke immediately after transient ischemic attack. Neurology 2004; 62:2015-20.
12. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MSV. Recurrent stroke and cardiac risks after first ischemic stroke. The Northern Manhattan study. Neurology 2006; 66:641-6.
13. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, Stewart-Wynne EG. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998; 29:2491-500.
14. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994; 25:333-7.
15. van Wijk I, Kapelle KJ, van Gijn J, Koudstaal PJ, Franke CL, Vermeulen M, Gorter JW, Algra A. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: A cohort study. Lancet 2005; 365:2098-104.
16. Chambers M, Noble I, Hollenbach F, Hutton J, Koch P. Stroke outcome model: Development of a decision-analytic model for economic analysis of stroke care [abstract]. Annu Meet Int Soc Technol Assess Health Care 1997; 13:137.
17. Nendaz MR, Sarasin FP, Junod AF, Bogousslavsky J. Preventing stroke recurrence in patients with patent foramen ovale: Antithrombotic therapy, foramen closure, or therapeutic abstention? A decision analytic perspective. Am Heart J 1998; 135:532-41.
18. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003; 34:1710-16.
19. Man-Son-Hing M, Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med 2002; 162:541-50.
20. Matchar DB, Pauker SG. Endarterectomy in carotid artery disease. A decision analysis. JAMA 1987; 258:793-8.
21. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87:144-52.
22. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial.The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998; 279:1265-72.
23. Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br Med J 2002; 324:71-86.
24. Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J 1995; 130 1083-8.
25. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G. Stroke recurrence in patients with patent foramen ovale: The Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology 1996; 46:1301-5.
26. Devuyst G, Bogousslavsky J, Ruchat P, Jeanrenaud X, Despland PA, Regli F, Aebischer N, Karpuz HM, Castillo V, Guffi M, Sadeghi H. Prognosis after stroke followed by surgical closure of patent foramen ovale: A prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound. Neurology 1996; 47:1162-6.
27. Bauer RB, Meyer JS, Fields WS, Remington R, Macdonald MC, Callen P. Joint study of extracranila arterial occlusion. 3. Progress report of controlled study of long-term survival in patients with and without operation. JAMA 1969; 208:509-18.
28. The Atrial Fibrillation Investigators.The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from three randomized trials. Arch Intern Med 1997; 157:1237-40.
29. O'Donnell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI, Ikeda D, Greenberg SM. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000; 342:240-5.
30. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology 2001; 56:773-7.
31. Kim SY, Martin N, Hsia EC, Pyeritz RE, Albert DA. Management of aortic disease in Marfan Syndrome: A decision analysis. Arch Intern Med 2005; 165:749-55.
32. Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med 2005; 118:625-35.
33. Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW, Wang PS. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol 2005; 25 427-34.
34. Balla JI, Elstein ES, Christiansen C. Obstacles to acceptance of clinical decision analysis. Br Med J 1989; 298:579-82.
35. Disch DL, Greenberg ML, Holzberger PT, Malenka DJ, Birkmeyer JD. Managing chronic atrial fibrillation: A Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med 1994; 120:449-57.
36. Johnston JA, Brill-Edwards P, Ginsberg JS, Pauker SG, Eckman MH. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism. Am J Med 2005; 118:503-14.
37. Boggess KA, Bailit JL, Singer ME, Parisi VM, Mercer BM. Projected benefits of universal or scheduled antepartum corticosteroids to prevent neonatal morbidity: A decision analysis. Am J Obstet Gynecol 2005; 193:1415-23.
38. Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: A decision analysis. J Clin Oncol 2005; 23 5178-87.
39. Venneman NG, Buskens E, Besselink MG, Stads S, Go PM, Bosscha K, van Berge-Henegouwen GP, van Erpecum KJ. Small gallstones are associated with increased risk of acute pancreatitis: Potential benefits of prophylactic cholecystectomy? Am J Gastroenterol 2005; 100 2540-50.
40. Castelnuovo E, Stein K, Pitt M, Garside R, Payne E. The effectiveness and cost-effectiveness of dual-chamber pacemakers compared with single-chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome: Systematic review and economic evaluation. Health Technol Assess 2005; 9(43):iIi, xi-xiii, 1-246.
41. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: A cost-effectiveness analysis. Am J Med 2005; 118:68-77.
42. Schwartzman K, Oxlade O, Barr RG, Grimard F, Acosta I, Baez J, Ferreira E, Melgen RE, Morose W, Salgado AC, Jacquet V, Maloney S, Laserson K, Mendez AP, Menzies D. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005; 353 1008-20.
43. Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Lung Cancer 2005; 48:171-85.
44. Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: Should we vaccinate? Pediatrics 2005; 115:1675-84.
45. Spermon JR, Hoffmann AL, Horenblas S, Verbeek AL, Witjes JA, Kiemeney LA. The efficacy of different follow-up strategies in clinical stage I Non-seminomatous Germ Cell Cancer: A Markov simulation study. Eur Urol 2005; 48:258-67.
46. Perreault S, Levinton C, Laurier C, Moride Y, Ste-Marie LG, Crott R. Validation of a decision model for preventive pharmacological strategies in postmenopausal women. Eur J Epidemiol 2005; 20:89-101.